The Asia Pacific Meningococcal Vaccine Market is expected to witness market growth of 9.9% CAGR during the forecast period (2020-2026).
Meningococcal vaccine manufacturers are focusing on the Asia Pacific region in order to capitalize for broadening treatment options for meningococcal disease in the region. As polysaccharide vaccines continue to show high traction from emerging countries owing to limited supply by limited vaccine manufacturers. That is why market forerunners team up with local distributors in order to expand their footprint. Furthermore, key market players, such as GlaxoSmithKline Plc., are capitalizing more to widening the range of age covered by meningococcal vaccines in the market.
The transmission of meningococcal bacteria, and unpredictable occurrences over time and across different age groups and geographies, have resulted in a substantial increase in the number of clinical programs for the effective development of meningococcal vaccines across the globe. Presently, around 30 ongoing clinical programs for the development of meningococcal vaccines at different stages. In the context of increasing government initiatives towards the development of meningococcal vaccines, the potential demand for these vaccines has increased.
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Scope of the Study
Market Segments covered in the Report:
By Brand
By Type
By Age Group
By Country
Companies Profiled
Unique Offerings from the Publisher
Meningococcal vaccine manufacturers are focusing on the Asia Pacific region in order to capitalize for broadening treatment options for meningococcal disease in the region. As polysaccharide vaccines continue to show high traction from emerging countries owing to limited supply by limited vaccine manufacturers. That is why market forerunners team up with local distributors in order to expand their footprint. Furthermore, key market players, such as GlaxoSmithKline Plc., are capitalizing more to widening the range of age covered by meningococcal vaccines in the market.
The transmission of meningococcal bacteria, and unpredictable occurrences over time and across different age groups and geographies, have resulted in a substantial increase in the number of clinical programs for the effective development of meningococcal vaccines across the globe. Presently, around 30 ongoing clinical programs for the development of meningococcal vaccines at different stages. In the context of increasing government initiatives towards the development of meningococcal vaccines, the potential demand for these vaccines has increased.
Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Scope of the Study
Market Segments covered in the Report:
By Brand
- Bexsero
- Trumenba
- Nimenrix
- Menactra
- Menveo
- Other Brands
By Type
- Bivalent
- Quadrivalent
- Other Types
By Age Group
- Infants (0 to 2 years)
- Children (2 years & above)
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Companies Profiled
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Sanofi S.A.
- Walvax Biotechnology Co., Ltd.
- Bio-Manguinhos (Oswaldo Cruz Foundation)
- Bio-Med Pvt. Ltd.
- Chongqing Zhifei Biological Products Co., Ltd.
- Hualan Biological Engineering, Inc.
- Incepta Pharmaceuticals Ltd.
- Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Unique Offerings from the Publisher
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Meningococcal Vaccine Market by Brand
Chapter 5. Asia Pacific Meningococcal Vaccine Market by Type
Chapter 6. Asia Pacific Meningococcal Vaccine Market by Age Group
Chapter 7. Asia Pacific Meningococcal Vaccine Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- GlaxoSmithKline PLC (GSK)
- Pfizer, Inc.
- Sanofi S.A.
- Walvax Biotechnology Co., Ltd.
- Bio-Manguinhos (Oswaldo Cruz Foundation)
- Bio-Med Pvt. Ltd.
- Chongqing Zhifei Biological Products Co., Ltd.
- Hualan Biological Engineering, Inc.
- Incepta Pharmaceuticals Ltd.
- Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Methodology
LOADING...
